Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BPMUFNASDAQ:DVAXNASDAQ:FLXNNASDAQ:ZFGNNASDAQ:ZIOP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$44.45$41.22$38.60▼$44.45$526.73M0.655 shsN/ADVAXDynavax Technologies$11.80+4.1%$12.35$10.06▼$15.15$1.54B1.262.04 million shs9.29 million shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/AZFGNZafgen$6.53+2.4%$18.47$0.62▼$2.76$244.68M0.27360,199 shs509,168 shsZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+9.08%+8.41%-14.52%DVAXDynavax Technologies-0.79%-5.58%-5.66%-18.71%+3.75%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%ZFGNZafgen-9.50%-11.63%-25.73%+47.00%+29.67%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ADVAXDynavax Technologies4.2944 of 5 stars3.41.00.04.72.52.51.9FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea PharmaceuticaN/AN/AN/AN/ADVAXDynavax Technologies2.75Moderate Buy$25.00111.86% UpsideFLXNFlexion TherapeuticsN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/ACurrent Analyst RatingsLatest ZIOP, FLXN, ZFGN, DVAX, and BPMUF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/23/2024DVAXDynavax TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/1/2024DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$20.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M3.00$1.13 per share39.34($0.94) per share-47.29DVAXDynavax Technologies$232.28M6.65N/AN/A$4.81 per share2.45FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.0014.92N/AN/AN/AN/AN/ADVAXDynavax Technologies-$6.39M-$0.06N/A27.44N/A-2.75%-1.08%-0.66%5/7/2024 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/AZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea PharmaceuticaN/A3.202.64DVAXDynavax Technologies0.4113.8112.96FLXNFlexion TherapeuticsN/A4.384.05ZFGNZafgen0.266.566.56ZIOPZIOPHARM Oncology0.183.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ADVAXDynavax Technologies96.96%FLXNFlexion Therapeutics90.01%ZFGNZafgen70.43%ZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ADVAXDynavax Technologies2.62%FLXNFlexion Therapeutics9.13%ZFGNZafgen14.20%ZIOPZIOPHARM Oncology5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14711.85 millionN/ANot OptionableDVAXDynavax Technologies408130.86 million127.43 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableZIOP, FLXN, ZFGN, DVAX, and BPMUF HeadlinesSourceHeadlineChildhood Cancerscuretoday.com - February 17 at 5:57 PMAlx Oncology Holdings (ALXO)investing.com - February 10 at 8:15 PMPediatric Hematology-Oncology Fellowshipbcm.edu - February 5 at 8:39 AMAlaunos Therapeutics: Other Events, Financial Statements And Exhibitscbonds.com - January 31 at 9:44 AMCG Oncology Increuters.com - January 31 at 4:43 AMOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patientsmedscape.com - December 21 at 3:43 PMImmuno-Oncologyajmc.com - December 19 at 3:21 PMWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?markets.businessinsider.com - December 18 at 8:18 AMExploring Patient-Centered Handoffs in Surgical Oncologymedscape.com - December 10 at 7:36 PMAssociation of Community Cancer Centersajmc.com - October 14 at 2:50 PMOncology News and Researchnews-medical.net - September 19 at 5:53 PMWBSPH 2024 - Oncologynewsweek.com - September 15 at 8:49 PMKris on Oncologymedscape.com - September 6 at 11:16 PMGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Resultsthestreet.com - August 29 at 6:23 AMOncology Cases & Quizzesmedscape.com - August 14 at 6:15 PMZiopharm’s palifosfamide fails in first-line STS…investing.com - June 21 at 12:05 AMWeber on Oncologymedscape.com - June 19 at 2:11 PMA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanomaascopubs.org - June 17 at 8:43 AMALX Oncology Holdings Inc Ordinary Sharesmorningstar.com - June 15 at 6:54 PMDivision of Pediatric Hematology and Oncologyslu.edu - June 13 at 3:50 PMDivision of Hematology and Medical Oncologyslu.edu - June 13 at 3:50 PMIntratumoral Cancer Therapies Global Market Report 2023finance.yahoo.com - June 9 at 1:32 PMNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.comarketwatch.com - May 11 at 9:52 PMVC Identifies 3 Startups That Will Shake Up the Future of Cancer Caremedcitynews.com - May 10 at 1:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBasilea PharmaceuticaOTCMKTS:BPMUFBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Dynavax TechnologiesNASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.ZIOPHARM OncologyNASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.